{
    "nct_id": "NCT03767582",
    "official_title": "A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).",
    "inclusion_criteria": "* Age ≥18 years.\n* Patients with histologically- or cytologically-proven, surgically unresectable, locally advanced pancreatic adenocarcinoma.\n* If the patient does not have a diagnostic biopsy that is adequate for review at our institution, the patient must agree to a research core biopsy to be performed at Johns Hopkins.\n* If the patient's available imaging is not adequate for review by our institution, the patient must agree to a repeat imaging to be performed at Johns Hopkins.\n* Patients cannot have had any prior therapy for the locally advanced pancreatic adenocarcinoma.\n* ECOG performance status 0 or 1\n* Life expectancy greater than 3 months.\n* Able to swallow pills or capsules.\n* Patient must have adequate organ function defined by the study-specified laboratory tests.\n* Patients must be eligible to receive FOLFIRINOX-based chemotherapy.\n* Patients must be willing to be treated with stereotactic body radiation therapy (SBRT) only at Johns Hopkins Hospital.\n* Patients must be willing to undergo a core biopsy of the pancreatic cancer.\n* Patients must be willing to undergo a biopsy of the pancreatic cancer if the patient is not deemed a surgical candidate during the pre-surgical evaluation.\n* Must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have had non-FOLFIRINOX-based chemotherapy for the pancreatic cancer.\n* Have received any anti-neoplastic biologics, vaccines or hormonal treatment, including investigational drugs, within 28 days of the first dose of study.\n* History of past treatment with immunotherapy agents prior to initial enrollment into this study (including, but not limited to: IL-2, interferon, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4 or anti-CCR2/5 drugs).\n* Have had prior organ or tissue allograft or allogeneic bone marrow transplantation, including corneal transplants.\n* Is currently participating or has participated in a study of an investigational agent or using an investigational device for the treatment of cancer.\n* Current use of immunosuppressive medications within 14 days prior to study medications.\n* Have received any vaccine within 14 days prior to study medications.\n* Receiving growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of the first dose of study medication.\n* History of any autoimmune disease. Patients with thyroid disease will be allowed.\n* Has a history of (non-infectious) pneumonitis or current pneumonitis.\n* Has a pulse oximetry < 92% on room air.\n* Requires the use of home oxygen.\n* Patients with uncontrolled intercurrent illness including, but not limited to, myocardial infarction or stroke/transient ischemic attack within the past 6 months, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* 12-lead electrocardiogram with QRS ≥ 120 msec, except right bundle branch block ; QTcF (QT corrected for heart rate using Fridericia's method) ≥ 480 msec, except right bundle branch block\n* Has an active infection requiring systemic therapy.\n* Infection with HIV or hepatitis B or C.\n* Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder cancer, early stage prostate cancer, or carcinoma in situ of the cervix.\n* Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could impact the absorption of study treatment.\n* Any gastrointestinal surgery that is likely impact upon the absorption of study treatment.\n* Inability to tolerate oral medication.\n* Unable to have blood drawn.\n* Have had surgery within 28 days of the first dose of study medication.\n* Prior use of strong/moderate CYP3A4 inhibitors or inducers within 28 days of the first dose of BMS-813160.\n* Prior use of Class I antiarrhythmics within 28 days of first dose of study medication.\n* Has ascites requiring medical management.\n* Presence of duodenal or gastric invasion by the tumor.\n* Hypersensitivity reaction to any monoclonal antibody.\n* Known allergy or hypersensitivity to study drugs or any of their components of the study arm that participant is enrolling.\n* Woman who are pregnant or breastfeeding.\n* Patient is unwilling or unable to follow the study schedule for any reason.",
    "miscellaneous_criteria": ""
}